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A B S T R A C T
In order to update the previous version of the European Code against Cancer and formulate evidence-
based recommendations, a systematic search of the literature was performed according to the
methodology agreed by the Code Working Groups. Based on the review, the 4th edition of the European
Code against Cancer recommends:
“Take part in organized cancer screening programmes for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women).”
Organized screening programs are preferable because they provide better conditions to ensure that
the Guidelines for Quality Assurance in Screening are followed in order to achieve the greatest benefit
with the least harm. Screening is recommended only for those cancers where a demonstrated life-
saving effect substantially outweighs the potential harm of examining very large numbers of people
who may otherwise never have, or suffer from, these cancers, and when an adequate quality of the
screening is achieved. EU citizens are recommended to participate in cancer screening each time an
invitation from the national or regional screening program is received and after having read the
information materials provided and carefully considered the potential benefits and harms of screening.
Screening programs in the European Union vary with respect to the age groups invited and to the
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of screening test used
For colorectal cancer, most programs in the EU invite men and women starting at the age of 50–60
years, and from then on every 2 years if the screening test is the guaiac-based fecal occult blood test or
fecal immunochemical test, or every 10 years or more if the screening test is flexible sigmoidoscopy or
total colonoscopy. Most programs continue sending invitations to screening up to the age of 70–75 years.
For breast cancer, most programs in the EU invite women starting at the age of 50 years, and not before
the age of 40 years, and from then on every 2 years until the age of 70–75 years.
For cervical cancer, if cytology (Pap) testing is used for screening, most programs in the EU invite
women starting at the age of 25–30 years and from then on every 3 or 5 years. If human papillomavirus
testing is used for screening, most women are invited starting at the age of 35 years (usually not before
age 30 years) and from then on every 5 years or more. Irrespective of the test used, women continue
participating in screening until the age of 60 or 65 years, and continue beyond this age unless the most
recent test results are normal.
ã 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltd https://creativecommons.
org/licenses/by-nc-nd/3.0/igo/Box 1. European Code against Cancer, 4th edition 2014.
EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1 Do not smoke. Do not use any form of tobacco.
2 Make your home smoke-free. Support smoke-free policies
in your workplace.
3 Take action to be a healthy body weight.
4 Be physically active in everyday life. Limit the time you
spend sitting.
5 Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and
fruits.
 Limit high-calorie foods (foods high in sugar or fat) and
avoid sugary drinks.
 Avoid processed meat; limit red meat and foods high in
salt.
6 If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.
7 Avoid too much sun, especially for children. Use sun
protection. Do not use sunbeds.
8 In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions.
9 Find out if you are exposed to radiation from naturally high
radon levels in your home. Take action to reduce high
radon levels.
10 For women:
 Breastfeeding reduces the mother’s cancer risk. If you
can, breastfeed your baby.
 Hormone replacement therapy (HRT) increases the risk
of certain cancers. Limit use of HRT.
11 Ensure your children take part in vaccination programs
for:
 Hepatitis B (for newborns)
 Human papillomavirus (HPV) (for girls).
12 Take part in organized cancer screening programs for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women).
The European Code against Cancer focuses on actions that
individual citizens can take to help prevent cancer. Success-
ful cancer prevention requires these individual actions to be
supported by governmental policies and actions.1. Introduction
The previous version of the European Code against Cancer [1]
recommended citizens to participate in regular screening for those
cancers amenable to it. Men and women from 50 years of age were
recommended to participate in colorectal screening; women from
25 years of age were recommended to participate in cervical
screening, and from 50 years of age to participate in breast
screening. All screening programs should have built-in quality
control procedures in compliance with the European Union
Guidelines for Quality Assurance in Screening [2–4].
In the European Union (EU), colorectal cancer is the third most
common cancer and the second leading cause of death due to
cancer, with more than 345,000 new cases and 150,000 deaths in
2012. Both men and women are at risk of developing colorectal
cancer. About one in 20 people will develop colorectal cancer
during their lifetime. About eight out of ten people who are
diagnosed with colorectal cancer are older than 60 years. About
five out of ten people diagnosed with colorectal cancer will die of
the disease; the risk of dying is lower if the cancer is detected at
screening [5]. In the EU, breast cancer is the most common cancer
and the most common cause of death due to cancer in women,
with about 365,000 new cases and 91,000 deaths per year. About
one in 10 women will be diagnosed with breast cancer during
their lifetime—mostly middle-aged and older women, but
younger women can also develop breast cancer. One in four
women with breast cancer will die from the disease. Breast cancer
in men is rare [5].
In the EU, there were about 34,000 new cases and more than
13,000 deaths due to cervical cancer in 2012. Rates of cervical
cancer are particularly high in many of the countries to the east and
south that acceded to the EU after 2003; rates of death due to
cervical cancer reported in Romania and Lithuania are seven times
higher than those in Finland [5]. The extreme differences result
primarily from the lack of or inadequate implementation of
organized cervical cancer screening programs in many countries
that have recently acceded to the EU [6].
The status of cancer screening programs in the EU is described
in the first report on implementation of the Council Recommen-
dation on Cancer Screening [6]. In 2007, over 64 million women in
the EU were targeted for breast cancer screening programs based
on mammography, and approximately 12 million women
attended (21 million women were invited by population-based
programs rolled out by EU member states). Approximately 146
million women were targeted by cervical cancer screening
programs which were running or being established in the EU
in 2007, and approximately 32 million women attended (17
million were invited by population-based programs rolled out by
EU member states). Approximately 107 million individuals weretargeted by colorectal cancer screening programs which were
running or being established in the EU in 2007, and approximately
12 million women and men attended (over 8 million were
personally invited by population-based programs rolled out by EU
member states) [6].
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against Cancer by formulating evidence-based recommendations,
a systematic search of the literature was performed according to
the methodology agreed by the Working Groups (WGs) involved in
the project [7]. Here, we present the new cancer screening
recommendations (see Box 1) and a summary of the evidence
retrieved. Based on this evidence, additional information was also
provided in the questions and answers section (Q&As) available
from the Code website [8].
2. Methods
A literature group composed of experts in systematic reviews
was appointed to identify and assess the scientific literature
relevant for the Code, adopting the following process (for more
details see [7]).
 The Screening WG defined clinical questions according to the
PICOS (population, intervention, control, outcome, study design)
methodology [7].
 Systematic bibliographic searches were performed on the
Cochrane Library, Medline, Embase, and PsycINFO from January
1st 2000 to January 31st 2013. Articles suggested by experts in
the field were also considered. If a large amount of literature for a
given topic was retrieved, preference was given in the first
instance to recently published (since 2007) systematic reviews. If
updated systematic reviews addressing the PICOS questions
were retrieved, the search for primary studies was limited to
those studies published after the last search date of the most
recently published systematic review [7].
 The methodological quality of retrieved systematic reviews and
primary studies was assessed using criteria extracted from
published and validated checklists [7].
 For each clinical questions, evidence tables and summary
documents with the most relevant clinical information and
the level of evidence were prepared [7]. The evidence was graded
according to the levels reported in Table 1.
 Finally, the evidence collected was presented and discussed
within the Screening WG [7]. Recommendations were made
based on consensus agreement obtained within the group [7].
3. Results
3.1. Recommendations
Taking the evidence into account, the 4th edition of the
European Code against Cancer (Box 1) recommends that people:
“Take part in organized cancer screening programmes for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women).”Table 1
Grading of levels of evidence.
Level Type of studies retrieved
I Multiple randomized controlled trials (RCTs
II One RCT of reasonable sample size, or three
III Prospective or retrospective cohort studies 
IV Retrospective case–control studies or their 
V Case series; before–after studies without a 
VI Expert opinion
Note: when results on side effects and/or benefits were derived from observOrganized screening programs are recommended because they
provide the best conditions to ensure that the European Union
Guidelines for Quality Assurance in Screening [2–4] are followed,
in order to achieve the greatest benefit with the least harm.
Screening is recommended only for those cancers where a
demonstrated life-saving effect substantially outweighs the
potential harm from examining very large numbers of people
who may otherwise never have, or suffer from, these cancers and
when adequate quality of the screening is achieved. It is
recommended to EU citizens to participate in cancer screening
each time an invitation from the national or regional screening
program is received and after having read the information
materials provided and carefully considered the potential benefits
and harms of screening. The WG agreed that the evidence on
benefits and harms for screening of other cancers, such as prostate
or lung cancer, at the time of the preparation of the Code was not
sufficiently available to recommend EU citizens to participate in
screening outside research programs, designed for evaluation and
implementation purposes. Screening programs in the European
Union vary with respect to the age groups invited and to the
interval between invitations, depending on each country's cancer
burden, local resources, and the type of screening test used.
For colorectal, breast and cervical cancer screening primary
test, age and interval between screening tests are reported (see
Box 2).
3.2. Scientific justification for the Code recommendations
The evidence on incidence and mortality of screening
according to age and intervals between tests, and on side effects
of colorectal, breast, and cervical cancer screening is presented
here, based on the clinical questions (PICOS) as formulated by the
Screening WG. The evidence retrieved on the impact of prostate
cancer screening on incidence and mortality is also presented. For
clarity, the PICOS used (original ones or simplified forms) are also
presented in the paragraphs below (Sections 3.2.1,3.2.2, 3.2.3 and
3.2.4)
3.2.1. Colorectal cancer screening
3.2.1.1. Effectiveness. Is the fecal occult blood test (FOBT) screening
offered to the general population effective in reducing colorectal
cancer mortality, colorectal cancer incidence, and overall mortality?
The results of a meta-analysis of published RCTs [9] demon-
strated that a guaiac-based FOBT (gFOBT) strategy appears to be
effective in reducing the colorectal cancer (CRC) mortality in
people at average risk, but not in reducing CRC incidence.
Combined results from the four eligible RCTs [9] showed that
participants allocated to gFOBT screening had a statistically
significant 16% reduction in the relative risk of CRC mortality:
relative risk (RR), 0.84; 95% confidence interval (95%CI): 0.78–0.90.
When adjusted for mean screening attendance in the individual
studies, there was a 25% relative mortality reduction (RR, 0.75; 95%
CI: 0.66–0.84) for those attending at least one round of screening) of reasonable sample size, or their systematic reviews (SRs)
 or fewer RCTs with small sample size
or their SRs; diagnostic cross-sectional accuracy studies or their SRs
SRs; time series analysis
control group, cross-sectional surveys
ational studies nested in RCTs, the level of evidence was not reported.
Box 2. Primary test, age and interval between tests for
colorectal, breast and cervical screening in organized
European programs.
Colorectal cancer screening:
- men and women starting at age 50–60 years,
- and from then on, every 2 years if the screening test is the
guaiac-based faecal occult blood test (gFOBT) or the fecal
immunochemical test (FIT),
- or every 10 years or more if the screening test is flexible
sigmoidoscopy (FS) or colonoscopy (TC).
Most programs continue sending invitations to screening up
to age 70–75 years.
Breast cancer screening:
- women starting at age 50 years and not before age of
40 years,
- and from then on, every 2 years until age 70–75 years.
Cervical cancer screening:
- Either cytology (Pap) testing or human papillomavirus
(HPV).
- If cytology is used for screening, women starting at age
25–30 years and from then on, every 3 or 5 years.
- If HPV testing is used for screening, women starting at age
35 years (usually not before age 30 years) and from then
on, every 5 years.
Irrespective of the test used, women continue participating
in screening until the age of 60 or 65 years, and continue
beyond this age unless the most recent test results are
normal.
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search there were no studies available of effectiveness of the
routine colorectal cancer screening programs with the guaiac-
based test.
According to evidence from an RCT, fecal immunochemical test
(FIT) screening reduces rectal cancer mortality, and from case–
control studies it reduces overall CRC mortality. After 8 years, a
significant 32% reduction in rectal cancer mortality but no
reduction in colon or overall CRC mortality were found [10]. The
following limitations should be considered: follow-up of positive
FIT was performed by flexible sigmoidoscopy (FS) instead of total
colonoscopy (TC), which may explain the lack of effect in the
overall CRC mortality. Furthermore, randomization was not based
on individuals but on townships. A significant reduction in CRC
mortality was observed in two Japanese case–control studies
[11,12], ranging from 52% to 83%, depending on years since last FIT
(level of evidence: II–IV). A significant reduction in advanced CRC
incidence – odds ratio (OR), 0.54, 95%CI: 0.30–0.99 – was observed
in one case–control study when FIT was performed within 3 years
before the diagnosis [13] (level of evidence: IV).
Is FIT superior to gFOBT in test performance characteristics?
Evidence from RCTs directly comparing gFOBT and FIT
demonstrates that the sensitivity of FIT for the detection of cancer
was significantly higher. The estimated specificity for not having
advanced neoplasia and CRC was lower, although not significantly
so, for FIT at a cut-off value of 100 ng/mL than that for gFOBT, while
it was similar to that of gFOBT with a cut-off value above 100 ng/mL
[14–16] (level of evidence: II). Also according to results coming
mainly from indirect comparisons in diagnostic cohort and case–
control studies, FIT seems to have a higher cross-sectional
sensitivity than gFOBT and a similar or lower specificity in
detecting CRC, although a meta-analysis of studies has not been
performed [17,18] (level of evidence: III). Evidence from multiple
population studies [14–16,19–22] and their meta-analyses of RCTsshows that FIT has a higher detection rate than gFOBT for advanced
neoplasia and cancer in both the per-protocol and intention-to-
treat analyses [23,24] (level of evidence: I). Furthermore,
randomized trials have consistently shown that FIT screening is
associated with higher uptake than gFOBT screening, presumably
because of easier test handling and the need for sampling of feces
from only a single bowel movements instead of three repeated
movements [16,20,25].
Is FS screening offered to the general population effective in
reducing CRC mortality, CRC incidence, and overall mortality?
The results of a meta-analysis of published RCTs demonstrate
that an FS-based strategy is effective in reducing the CRC mortality
and incidence in average-risk people [26]. When results from five
RCTs [27–31] were combined, a statistically significant 28%
reduction in the relative risk of CRC mortality (RR, 0.72; 95%CI:
0.65–0.80) was observed in the invited population (intention-to-
treat analysis). Among people participating (per-protocol analysis),
a 50% reduction in the relative risk was observed among subjects
undergoing the examination (RR, 0.50; 95%CI: 0.35–0.64) [26]
(level of evidence: I).
When results from four RCTs [27,29–31] were combined, a
statistically significant 18% reduction in the relative risk of CRC
incidence (RR, 0.82; 95%CI: 0.73–0.91) was observed in the
intention-to-treat analysis. In the per-protocol analysis, a statisti-
cally significant 32% reduction in the relative risk was observed
among subjects undergoing the examination (RR, 0.68; 95%CI:
0.47–0.89) (level of evidence: I).
Is TC screening offered to the general population effective in
reducing CRC mortality, CRC incidence, and overall mortality?
Observational evidence exists on the efficacy of TC screening in
reducing CRC mortality and incidence [32–43]. Results from RCTs
evaluating CRC mortality and incidence as primary endpoints in
screening colonoscopy are not available. Results of studies
including subjects undergoing at least one colonoscopy, irrespec-
tive of a positive or negative result (both subjects undergoing
adenoma removal and/or colonoscopic surveillance because of a
positive result, and subjects with no adenomas at colonoscopy are
included), show a significant mortality and incidence reduction,
ranging from 29% to 65%, in the relative risk of CRC mortality, and
from 48% to 67% in the relative risk of CRC incidence. Reduction in
the overall CRC mortality and incidence is always significant;
however, stratification by site suggests that colonoscopy might not
be as effective in the proximal colon as in other segments of the
colon/rectum (level of evidence: III–IV).
3.2.1.2. Age range and screening interval. What is the optimal age
range in which to perform screening with FOBT as the primary
screening test, and what is the best time interval for offering screening
by FOBT?
In the trials analyzing gFOBT as the primary screening test, the
age range of subjects included is 45–80 years. In these trials the
observed mortality reduction is significant, and they include
analyses of the whole age ranges, with follow-up times varying
from 11.7 to 18 years between the trials. None of the RCTs
investigating annual or biennial screening gFOBT reported a formal
subgroup analysis of efficacy in different age groups [44–47]. Data
from the Nottingham trial at 11 years of follow-up showed no
difference in CRC mortality rates between subjects older and
younger than 65 years [48], but when separate results were
reported for age subgroups after a median of 19.5 years, the
Nottingham RCT [49] showed that there was a significant reduction
in CRC mortality for the age group older than 60 years but not for
the age group younger than 60 years (level of evidence: II). No
evidence is available on the best age range for FIT screening. Given
the similarities between the tests, the age range can be based on
the evidence for the optimal age range from gFOBT trials.
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and biennial screening. Both intervals were found to be effective in
reducing CRC mortality, with the benefit from annual screening
appearing to be greater than that for biennial screening, although
not significantly different [50] (level of evidence: II). Case–control
studies suggest that the effect of FIT on colorectal cancer mortality
was significant only in those subjects screened within 3 years
before the diagnosis, although power may have been an issue for
longer intervals [11–13] (level of evidence: II–IV). A population
screening study has shown that repeated FIT screening with a 1, 2,
or 3-year interval led to a similar diagnostic yield of advanced
neoplasia [51].
What is the optimal age range in which to perform screening with
FS as the primary screening test, and what is the best time interval for
offering screening by FS?
For FS as the primary screening test, no significant differences
for any outcome have been observed between ages 55–59, 60–64,
and 65–74 years according to the results of the trials in the UK,
Italy, and the United States [29–31] (level of evidence: I). According
to the results from published RCTs, the reduction in incidence/
mortality still remains after 10–11 years of follow-up, and
therefore the interval for offering screening could be longer than
10 years (level of evidence: I). In a study in which FS was offered
within 5 years of the previous one, no increase in the effect was
observed compared to the results of the RCTs offering FS once in a
lifetime and with a similar duration of follow-up. [31].
What is the optimal age range in which to perform screening with
TC as the primary screening test, and what is the best time interval for
offering screening by TC?
Available evidence on the age range for TC as the primary
screening test includes subjects 50 years and suggests that the
impact is lower among elderly people (>75 years). Available
evidence on colonoscopy intervals suggests that interval of at least
10 years is sufficient [32–35,40–42] (level of evidence: III–IV).
3.2.1.3. Negative side effects. What is the rate of negative side effects
of FOBT screening?
Rates of minor and severe complications
The results of RCTs demonstrate that the FOBT strategy is safe,
with no direct adverse effects. Complications in an FOBT program
occur from colonoscopies after positive test results [9] (level of
evidence: I).
False-positive results
FOBT is associated with false-positive results, leading to anxiety
and unnecessary follow-up colonoscopies. The positive predictive
value for CRC and advanced adenoma was estimated respectively
at 11% and 40% for gFOBT and 9% and 38% for FIT [16], and
respectively 10% and 45% for gFOBT and 10% and 53% for FIT [14].
False-negative results
According to the review of 19 diagnostic cross-sectional studies
for the diagnosis of all neoplasms (11 cohort studies and eight
case–control studies), sensitivity for CRC ranged from 25% to 79% in
cohort diagnostic accuracy studies with follow-up [52].
Acceptability, psychological effects
Results on the impact of screening on daily life and levels of
anxiety after a positive FOBT result are reported in the review [52]
of three RCTs [53–55]. For people with a false-positive FOBT result,
the highest anxiety levels occurred after notification of a positive
test and before colonoscopy, the lowest one was experienced the
day after colonoscopy, and it remained low 1 month later [53].
Among invited people, 46% were worried by the invitation and
refused to participate [54]. Among participants,16% reported being
“extremely” worried [54]. Among 54 people with a false-positive
FOBT result, 68% reported experiencing distress [55].
What is the rate of negative side effects of FS screening?
Rates of minor and severe complicationsRates of peritonitis-like reaction, glutaraldehyde colitis, allergic
reaction to latex gloves, self-limited bleeding, and mild vagal
reactions (nausea, feeling faint or feeling dizzy, abdominal pain)
from FS range from 0.2% to 0.6%. Rates of hospitalization within 30
days due to serious hemorrhage involving transfusion, or due to
perforation, from FS range from 0% to 0.03%. Rates of severe
complications with follow-up colonoscopy are about 10 times
higher [28,31,56–59].
False-negative results, interval cancers
Prospective follow-ups of negative screening FS in average-risk
populations showed that approximately 0.8% of subjects had
advanced neoplasia in the distal colon viewed on a second FS
conducted 3 years later, and no adenocarcinomas were detected in
the distal colon 3 years after a negative screening examination
[60,61].
RCTs on long-term impact of FS and interval cancers [31,62]
reported a risk of interval distal cancer after a negative FS of 0.07%
(33/44,988) after a mean of 11.5 years. In the SCORE trial, among
subjects with negative screening examination results the rate of
CRC incidence (interval cancers) remained lower than in the
control group over the entire follow-up period (Nelson–Aalen
cumulative hazard ratio 0.41; 95%CI: 0.32–0.54; 0.21; 95%CI: 0.13–
0.32) when considering only distal CRCs [30].
Acceptability, psychological effects
Results from RCTs and studies on patient-reported experiences
after FS in a community-based FS screening program show that FS
should be considered an acceptable test.
In the context of the UK FS screening trial [56], 80% of
participants responding to a questionnaire on the morning after
the test reported no pain or only mild pain during the FS screening
examination; 3% described the pain as severe. Three months after
the FS, 98% were glad that they had had the test, and 97% would, if
asked by a friend, encourage them to have the test. In the context of
the NORCCAP trial [63], 70% of participants responding to a
questionnaire immediately after the FS reported having experi-
enced no pain, and 21% reported experiencing slight pain during
the examination. During the PLCO trial [64], 75% said that they
would strongly recommend the procedure to their friends; 76%
strongly agreed or agreed that the examination did not cause a lot
of pain, and 15–25% indicated that they had experienced a lot of
pain, great discomfort, or more discomfort than expected. During
the SCORE trial [58], 95% of people undergoing FS completed a
short questionnaire administered immediately after the test; 60%
reported mild discomfort, 23% reported the test to be less painful
than expected, and 2% described the pain as the most severe they
had ever experienced. In each study, women were more likely to
have significant pain or discomfort than men.
What is the rate of negative side effects of TC screening?
Rates of minor and severe complications
Rates of severe complications (death, cardiopulmonary events,
bleeding, perforation, other clinically relevant complications) from
TC (including complications from polypectomy) reported in three
European national screening programs [65–67] and in an ongoing
RCT in eight Spanish regions [68] range from 0.06% to 0.5%. Pox
2012 reported also the complication rate in colonoscopies with
polypectomy separately from that in colonoscopies without
polypectomy (OR, 4.9; 95%CI: 4.6–5.2), and the rate of minor
complications (1.9 per 1000).
False-negative results, interval cancers
The miss rate for adenoma 10 mm estimated in studies by
colonoscopy with segmental unblinding ranges from 0 to 12 per
100 [69–73]. From published data from a colonoscopy-based
screening program in Poland [74], it has been observed that after a
mean follow-up of 52.1 months, the risk of interval CRCs between
screening colonoscopy and scheduled surveillance examination
was 0.09% (42/45026).
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Results from studies on patient-reported experiences after
colonoscopy as the primary screening test [75–81] show that the
majority of patients experienced at least moderate discomfort
associated with the laxative bowel preparation and perceived it to
be the worst part of the colonoscopy [82]. Other reported
difficulties were the pre-test fasting and liquid diet, pre-procedural
anxiety, worry and anticipation of pain, the instrument insertion,
as well as embarrassment with the process, and the length of the
procedure that required time away from other duties. In the
studies that took pre- and post-test measurements, it appeared
that patients experienced less discomfort and pain than expected
and/or reduced concerns and anxiety after the procedure
[76,79,80]. In all these studies, intravenous sedation was used.
When analyzing the results of a 30-day active follow-up among
average-risk people undergoing FS, TC, and FIT [83], the proportion
of people complaining of serious reactions after bowel preparation
(OR, 5.17; 95%CI: 3.70–7.24) or reporting severe pain immediately
after the examination (OR, 1.86; 95%CI: 1.47–2.34) was higher for
TC than for FS. The most common post-procedural complaints
were abdominal distension and pain.
3.2.2. Breast cancer screening
3.2.2.1. Effectiveness. Is mammography screening effective in
reducing breast cancer mortality in the general female population
at average risk of breast cancer?
Three meta-analyses of RCTs [84–86] found a statistically
significant reduction in breast cancer mortality when women of all
age ranges between 40 and 74 were considered together (RR, 0.81;
95%CI: 0.74–0.87, nine trials included [84]; RR, 0.82; 95%CI: 0.74–
0.91, nine trials included [85]; RR, 0.80; 95%CI: 0.73–0.89, nine
trials included [86]). Different meta-analyses include different
trials, durations of follow-up, and definitions of outcome.
Nevertheless, there is general agreement in their estimates of an
approximate 20% reduction in relative risk of breast cancer
mortality from invitation to screening (level of evidence: I).
Results from observational studies considering women invited
to screening (intention-to-treat analysis) pooled in meta-analyses
confirmed the effectiveness of screening in reducing breast cancer
mortality [87,88]. The pooled mortality reduction among invited
women in seven incidence-based mortality studies was 25% (RR,
0.75, 95%CI: 0.69–0.81), and in seven case–control studies it was
31% (OR, 0.69; 95%CI: 0.57–0.83) [87]. When only women who
actually received mammography screening were included in the
analysis (per-protocol analysis), the estimate of mortality reduc-
tion was significantly higher. Among those actually screened, the
pooled mortality reduction in the incidence-based mortality
studies was 38% (RR, 0.62; 95%CI: 0.56–0.69) and in the case–
control studies it was 48% (OR, 0.52, 95%CI: 0.42–0.65), when
adjusted for self-selection [87]. When trend studies were
considered, 12 of the 17 trend studies retrieved by Broeders
et al. [87] quantified the impact of population-based screening on
breast cancer mortality. The estimated reductions in breast cancer
mortality ranged from 1% to 9% per year in studies reporting an
annual percentage change, and from 28% to 36% in those
comparing post- and pre-screening periods over study time
periods ranging from 15 to 30 years. [87] (level of evidence: III–IV).
3.2.2.2. Age range and screening interval. What is the optimal age
range in which to perform mammography screening for breast cancer,
and what is the optimal time interval for such screening?
All meta-analyses of both RCTs [84–86] and observational
studies [87,88] of invitation to breast cancer screening found a
statistically significant reduction in breast cancer mortality whenwomen of all age ranges between 40 and 74 were considered
together (level of evidence: I–III).
When narrower age ranges were considered separately, the
reduction in breast cancer mortality was greatest for women in the
age range 60–69 years (RR, 0.69, 95%CI: 0.57–0.83, five trials
included [85]; RR, 0.68, 95%CI: 0.54–0.87, two trials included [89])
(level of evidence: I). For the age ranges 40–49 and 50–59 years, the
reduction in mortality was statistically significant even though it
was less than for the age ranges 40–74 (40–49 years: RR, 0.85; 95%
CI: 0.75–0.96, eight trials included [85,89]; 50–59 years: RR, 0.82;
95%CI: 0.68–0.98, seven trials included [85], RR, 0.86; 95%CI: 0.75–
0.99, six trials included [89]) (level of evidence: I). For women aged
70–74 years, the results indicating a reduction in breast cancer
mortality were nearly statistically significant (RR, 0.68; 95%CI:
0.45–1.01, two trials included [85]; RR, 1.12; 95%CI: 0.73–1.72, one
trial included [89]) (level of evidence: I).
Results from observational studies and considering different
age ranges were reported by Gabe et al. [88] for women younger
than 50 years. Four cohort and non-RCT comparative studies
reported results separately for women younger than 50 years. In
the age range 45–49 years in the UK TEDBC study [90], there was a
relative risk of 0.70 (95%CI: 0.57–0.86) for breast cancer mortality
in cases diagnosed within 7 and 10 years of entry and a
corresponding relative risk of 0.74 (95%CI: 0.64–0.85) for women
aged 50–64 years. After adjustment for self-selection bias in
women aged 40–49 years, a relative risk of 0.52 (95%CI: 0.40–0.67)
was observed in those screened in the study of Tabar et al. [91].
Such a benefit was not observed in the comparative study in
women aged 35–49 years in the Netherlands [92], with a relative
risk of 0.94 (95%CI: 0.68–1.29) after 16 years of follow-up. In a
study of all Swedish counties (except those participating in the
randomized studies) [93], the estimated relative risk associated
with invitation was 0.91 (95%CI: 0.72–1.15) in women aged 40–49
years (level of evidence: III–IV). A more recent study including all
Swedish counties compared breast cancer mortality among
women who were invited to service screening at ages 40–49
years (study group) and women in the same age group who were
not invited during 1986–2005 (control group). The average follow-
up was 16 years. The estimated RR for women who were invited to
screening was 0.74 (95%CI, 0.66–0.83), and the RR for women who
attended screening was 0.71 (95%CI, 0.62–0.80) [94]
From available evidence on interval cancers, in the age range
40–49 years the proportional incidence (i.e. the interval cancer
incidence as a proportion of the underlying breast cancer incidence
rate) within 12 months was 43% (95%CI: 30.4%–54.7%) and within
13–24 months it was 67% (95%CI: 55.1–79.8%); the confidence
intervals do not overlap [95] (level of evidence: I–III). For the age
range 50–59 years, available studies showed a proportion of about
25% within 11 months, and about 50% within 12–23 months;
confidence intervals were not reported [96] (level of evidence: II–
III).
From available evidence from RCTs on breast cancer mortality,
when considering the age range 40–49 years, one RCT estimated a
significant reduction in mortality for an interval <24 months. For
the age range 50–69 years, a significant reduction in mortality was
observed for an interval of 24–33 months, and for the age ranges
from 39–69 when the interval was <24 months [85] (level of
evidence: I–II).
3.2.2.3. Negative side effects. What is the (cumulative) false-positive
rate in the screening age period?
Lynge et al. [96] reported data from 17 national or regional
programs: false positives as a percentage of negative/normal
results after further non-invasive assessment, after a single
screening round, ranged from 0.7% to 17.5% (median 5%). False
positives as a percentage of negative/normal results after a
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[96]. According to a review of studies performed after 2000 in the
context of European mammography screening programs (for a
total of 390,000 screened women aged 50–69 years undergoing ten
biennial screening tests), the estimated cumulative risk of a false-
positive screening result varied from 8% to 21%, and the cumulative
risk of an invasive procedure with a benign outcome ranged from
1.8% to 6.3%; the estimated cumulative risk of a false-positive
screening result without an invasive procedure was 16.8%, and the
risk of undergoing surgical intervention with benign outcome was
0.9% [97]. According to the cross-sectional information collected by
the European Network for Information on Cancer project (EUNICE),
the proportions of all screening examinations in the programs
resulting in needle biopsy were 2.2% for initial screening and 1.1%
for subsequent screenings (the rates differed between countries);
the corresponding rates of surgical interventions among women
without breast cancer were 0.19% and 0.07% [97] (level of evidence:
III).
What is the risk of overdiagnosis in the screening process?
The results of the reported systematic reviews of published
RCTs or observational studies agreed in demonstrating that a
mammography program could cause harm, including the possibil-
ity of overdiagnosis. Overdiagnosis is the diagnosis of breast cancer
which would never have surfaced as clinically diagnosed cancer
during the women's lives, without screening, leading to unneces-
sary treatment.
Overdiagnosis has been assessed and evaluated in several ways
among the systematic reviews and meta-analyses considered,
suggesting that the existing phenomenon is difficult to define and
determine.
Estimates of risk of over-diagnosis from RCTs are the following:
30% [84], 19% (95%CI 15–23) (when overdiagnosis is defined as
excess cancers as a proportion of cancers diagnosed during the
active screening period in women invited for screening) and 11%
(95%CI 9–12) (when overdiagnosis is defined as excess cancers as a
proportion of cancers diagnosed in the long term in women invited
for screening) [86].
Estimates of overdiagnosis, expressed as a percentage of the
expected incidence in the absence of screening from population-
based mammography screening in seven Western European
countries (the Netherlands, Italy, Norway, Sweden, Denmark, the
UK, and Spain) adjusted for breast cancer risk and lead-time bias
are the following: Netherlands, 2.8%; Italy, 4.6% and 1.0%; Denmark,
7.0%; England and Wales, 10% and 3.3%; no reliable estimates were
available for Norway, Sweden or Spain. The estimates of risk of
overdiagnosis unadjusted or incompletely adjusted for breast
cancer risk and lead-time bias ranged from 0% to 54%.
According to the previous considerations, the most plausible
estimates of risk of overdiagnosis range from 1% to 10% [98] (level
of evidence: I–III).
What about the other harms/negative side effects/adverse effects of
mammography screening?
Pain
Mammography is considered an acceptable test. According to
the results of the review on screening mammography in women
40–49 years of age by Armstrong 2007, few women agreed that the
pain caused by mammography would prevent them from
attending future screening. The degree of pain was associated
with the stage of menstrual cycle, anxiety, and pre-mammography
anticipation of pain [99].
Psychological effects
Brett et al. [100] reviewed 54 studies from 13 countries, and
according to these results the negative psychological impact of
mammography screening was minimal in women who received a
negative result after mammography. Initial anxiety on receipt of
the invitation declined at receipt of a clear result after screening.However, the negative psychological impact of a false-positive
result appears to be significant prior to the recall appointment, at
the recall appointment, and after recall (despite a clear result)
[100].
Bond et al. [101] found that having a false-positive screening
mammography result can cause breast-cancer-specific distress for
up to 3 years, related to the invasiveness of the assessment. In
addition, women placed on early recall were also at a greater
relative risk of distress. According to results from studies retrieved
by Bond et al. [101], women with false-positive mammography
results were less likely to return for routine assessment than those
with normal ones (RR, 0.97; 95%CI: 0.96–0.98), while according to
Brewer et al. [102] the effect was not statistically significant among
European women (risk ratio, 0.97; 95%CI: 0.93–1.01). Women who
received false-positive results conducted more frequent breast
self-examinations and had higher, but apparently not patholog-
ically elevated, levels of distress and anxiety, and thought more
about breast cancer than did those with normal results [102].
Overall, the psychological impact of mammography screening is
minimal in women who received a negative result after
mammography, while it appears to be negative in women who
received a false-positive result.
Radiation exposure
Radiation studies have estimated the risk of induced breast
cancer due to repeated mammography exposure. These studies
have not measured the excess risk of breast cancer directly; instead
they model the data from studies assessing radiation effects in
other settings. The excess risk of breast cancer induced by radiation
depends on the X-ray dose of mammography and the age when
starting screening. The risk of breast cancer induced between the
ages of 40 and 80 years with annual mammography is 1 per 1000
women. The risk–benefit ratio between 40 and 49 years is one
death induced by cancers due to radiation exposure versus three
saved lives. For mammography, it is predicted that the excess
relative risk (ERR), defined as proportion of RR due solely to
radiation exposure (ERR = RR –1), doubles when screening starts at
age 40 instead of 50. Other estimates predict that biennial
screening starting at age 50 and continuing until age 74 causes 7.7
breast cancers and 1.6 breast cancer deaths per 100,000 women
aged 0–100 [103–108] (level of evidence: III, modelling studies).
3.2.2.4. Positive side effects. What is the frequency of mastectomy
and breast-conserving surgery for women participating in breast
cancer mammography screening?
All cohort studies found that screen-detected breast cancers
overall are at an earlier stage and have more favorable tumor
characteristics (size, stage, grade) [109–119]. Hofvind et al. [111]
found an increased percentage of breast-conserving surgery and a
reduced percentage of mastectomies among participating women;
Giorgi Rossi et al. [110] found a non-significant reduction in the
percentage of mastectomy, and a lower proportion of treatment
that was not appropriate for the stage of the disease among invited
women. All the other studies found a higher rate of breast-
conserving surgery and a reduction in mastectomy compared with
cancers detected in women not screened (level of evidence: III).
The following results from population trend studies were
retrieved: two studies found a significant decline in the rate of
radical mastectomy and an increase in breast-conserving surgery
[120,121]. Coburn et al. [122] assessed the rate of breast-
conserving surgery and found an increase. Stang et al. [123] found
an increase in breast-conserving surgery, while mastectomy rates
showed little change over time. Ernst et al. [124,125] and Suhrke
et al. [126] did not find a significant increase in breast-conserving
surgery or a decline in mastectomy rates (level of evidence: IV).
The retrieved cross-sectional study [127] found that women
who underwent mammography screening had smaller tumors,
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consider breast conservation as an alternative to mastectomy
(level of evidence: V).
All [128–131] but one [132] case series studies found an
increase in the rate of breast-conserving surgery and a decrease in
the mastectomy rate; in two studies the difference was statistically
significant (level of evidence: V).
Overall, most of the studies showed a decrease in the rate of
mastectomies and an increase in the rate of breast-conserving
surgery among women participating in breast cancer screening.
What are the other positive side-effects of mammography
screening in terms of the incidence rates of advanced cancer?
Different study designs give not fully consistent results
concerning the impact of breast cancer screening on the incidence
of advanced breast cancer. An analysis of the 29-year follow-up
data from the Dalarna County component of the Swedish Two-
County Trial [133] concluded that the slight proportional deficit in
invasive cancers in the active study population at 29 years of
follow-up might be due to the detection and removal of carcinoma
in situ, and that the long-term reduction in advanced cancers is
consistent with the long-term reduction in breast cancer mortality
observed in the trial (level of evidence: II).
Two cohort studies [111,112] found that breast cancers detected
with screening have favorable tumor characteristics compared
with those diagnosed in the pre-screening period and outside the
program, and that advanced-stage breast cancer is less common in
women invited and participating in the program than in women
invited but not participating. A significant and stable decrease in
the incidence of late-stage breast cancer was observed from the
third year of screening onward, when the ratio of observed to
expected incidence rate varied between 0.81 and 0.71 in 700
municipalities, having a total population of 692,824 women aged
55–74 years targeted by organized mammography screening
between 1991 and 2005 [134] (level of evidence: III). One cross-
sectional study [135] compared the prevalence of advanced cancer
detected after 2 years in counties with mammography facilities
versus counties without mammography facilities and found a
significant association between the absence of in-county mam-
mography facilities and a high probability of diagnosis at a late
stage of breast cancer (level of evidence: V).
Three population trend studies [136–138] with 12, 15, and 32
years of follow-up found a not significant reduction in advanced
cancers, or no decline in advanced breast cancer was detected
(level of evidence: IV).
Overall, most of the studies found a decrease in the incidence of
advanced cancers in populations targeted by organized mammog-
raphy screening.
3.2.3. Cervical cancer screening
3.2.3.1. Effectiveness. Is screening for cervical cancer effective in
reducing cervical cancer incidence and mortality?
Evidence of effectiveness of conventional cytology testing with
Papanicolaou staining is derived from observational studies:
cohort studies involving follow-up of screened women, case–
control studies, as well as time trend studies and ecological or
geographical correlation studies [31,39]. Significant reduction in
incidence of invasive cancer from cytology testing observed in
cohort studies ranged from 80% to 30% [139]. Pooled analysis from
case–control studies showed a significant reduction in incidence of
66% (OR, 0.34, 95%CI: 0.31–0.38) [139]. The impact of the reduction
was greater in countries that conducted organized screening than
in countries that did not (level of evidence: III–IV).
One large cluster-randomized trial provided cervical cancer
mortality and incidence outcomes for women with a single lifetime
screen – cytology or human papilloma virus (HPV) test – comparedwith women with no screening history. After 8 years of follow-up,
the risk of advanced cervical cancer was 53% significantly lower
(HR, 0.47; 95%CI: 0.32–0.69) and cervical cancer mortality was 48%
significantly lower (HR, 0.52; 95%CI: 0.33–0.83) among women in
the HPV-testing group. No significant reductions in the numbers of
advanced cancers or deaths were observed in the cytology-testing
group [140] (level of evidence: II).
A recent pooled analysis of follow-up data from four RCTs
conducted in Sweden (Swedescreen), the Netherlands (POBAS-
CAM), England (ARTISTIC), and Italy (NTCC) has demonstrated that,
compared to cytology, HPV-based screening provides 60–70%
greater protection against invasive cervical carcinomas; the
respective pooled rate ratio for invasive cervical carcinoma among
women with a negative screening test at entry was 0.30 (95%CI
0.15–0.60) [141] (level of evidence: I).
RCTs used different strategies for managing HPV-positive women
(by cytology triage or direct referral to colposcopy), and for primary
screening using primary HPV testing alone, or in combination with
cytology. The biopsy rate was doubled (rate ratio 2.24; 95%CI: 2.09–
2.39) in the NTCC trial, where all HPV-positive women were directly
referred for colposcopy, while it was not increased in studies using
cytological triage (POBASCAM, Swedescreen, ARTISTIC) [141] (level
of evidence: I). Co-testing of all women with both HPV and cytology
compared with primary HPV testing alone led to increased
unnecessary colposcopy [142,143] (level of evidence: I). As the
efficacy results were similar, the data support the use of the least
extensive strategy (primary HPV screening with triaging by cytology
before referral) (level of evidence I).
3.2.3.2. Age range and screening interval. What is the optimal age
range in which to perform cervical cancer screening, and what is the
best time interval for such screening?
Evidence based on cohort and case–control studies shows that
HPV infections and cytological abnormalities among women
younger than 25 years are common and transient, whereas cervical
intraepithelial neoplasia of grade 3 or worse (CIN3+) is much less
common in this group than in women aged 25 years and older
[144,145]. Cytology screening in women younger than 25 years has
lower detection rates, higher false-positive rates, and lower
effectiveness than in older women [146] (level of evidence: III–IV).
HPV testing is more sensitive than cytology [147,148]. HPV testing
was substantially more sensitive in detecting CIN2+ than cytology
(96.1% versus 53.0%) but less specific (90.7% versus 96.3%). HPV
sensitivity was uniformly high at all ages, whereas the sensitivity of
cytology was substantially better inwomen over the age of 50 than in
younger women (79.3% versus 59.6%). The specificity of both tests
increased with age, but loss in specificity with HPV testing versus
cytology is very large at young ages [149]. Specificity of HPV testing
can increase by increasing the screening interval [150] or by triaging
HPV-positive women with cytology [151].
In pooled data from four RCTs [141] considering age at
enrolment, the lowest rate ratio (0.36, 95%CI: 0.14–0.94) was
noted in women aged 30–34 years. However, the efficacy of HPV
testing did not differ significantly between women aged 30–34
years and those 35 years and older (P = 0.13). These results suggest
a gain in efficacy with HPV testing, starting at age 30 years (data at
younger ages are too sparse to draw conclusions) [141] (level of
evidence: I).
When considering age at which to stop screening in an HPV-
negative woman, the risk of acquiring a new infection and the long
time needed for progression from infection to invasive cancer
should be taken into account. In Europe the prevalence of infection
by oncogenic HPV types strongly decreases with age up to about
age 45; it remains fairly constant after that age [144], and little is
known about the age-specific occurrence of new infections. Also,
no CIN3 was detected during the second round of screening among
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were detected in the cytology group [152]. These issues suggest a
longer protection of HPV screening at older ages and an earlier age
at which to stop screening than with cytology screening [151].
Evidence of reduced risk of cervical cancer after a negative Pap
smear result was reported in the IARC multicentre study [153]. The
reduction in cumulative incidence of invasive squamous-cell
carcinomas of the cervix uteri was reported at 93% when screening
every year, 91% when screening every 3 years, and 84% when
screening every 5 years, with follow-up among women aged 35–64
years who had at least two previous negative smears [153].
Estimation of the relative risk of carcinoma of the cervix uteri in the
Netherlands following a negative screening result, compared with
the risk in the absence of screening [154] indicates that almost as
much benefit is expected from 3-yearly screening as from annual
rescreening among women aged 35–64 years. The same relative risk
stratified by age was estimated in England using non-screened
women for comparison [155]: among women aged 20–39 years, a
30% risk reduction was observed at 3.5 years; among women aged
40–54years,a40% riskreductionwasobservedat5 years; and among
women aged 55–69 years, a 70% risk reduction was observed at 5
years since the negative test (level of evidence: III–IV).
According to pooled data from the Swedescreen, POBASCAM,
ARTISTIC, and NTCC RCTs, when HPV-based screening for cervical
cancer was compared with cytology-based cervical screening, the
cumulative incidence of invasive cervical carcinoma in women
with negative entry tests was 4.6 per 105 (95%CI: 1.1–12.1 per 105)
at 3.5 years and 8.7 per 105 (95%CI: 3.3–18.6 per 105) at 5.5 years in
the HPV-based screening arm; the respective resultsin the
cytology-based cervical screening arm were 15.4 per 105 (95%CI:
7.9–27.0 per 105) at 3.5 years and 36.0 per 105 (95%CI: 23.2–53.5
per 105) at 5.5 years. The recorded cumulative incidence of cervical
cancer was lower 5.5 years after a negative HPV test than 3.5 years
after a negative cytology result, indicating that 5-year intervals for
HPV screening are safer than 3-year intervals for cytology [141]
(level of evidence: I).
Irrespective of the test used, the European guidelines recom-
mend that women continue participating in screening until the age
of 60 or 65 years, and beyond this age if the most recent test
results are not normal [3].
3.2.3.3. Negative side effects. What is the risk of overdiagnosis in the
cervical cancer screening process?
CIN is a pre-invasive lesion, and one out of every four to seven
progress to an invasive lesion if not treated. It could be concluded
that diagnoses of non-progressive lesions are cases of overdiagno-
sis, but progressive lesions cannot be distinguished from regressive
ones. Results of studies estimating additional overdiagnosis from
HPV testing are reported here. Overdiagnosis of regressive lesions
has been evaluated in RCTs by comparing the overall detection of
regressive lesions in the HPV arm and in the cytology arm up to the
second screening round and beyond. No difference between arms
in the cumulative incidence of CIN2 and CIN3+ up to the second
round in women aged 29–33 years was observed in POBASCAM,
the RCT in which the HPV test was applied at the second round
[156]. Data from RCTs applying cytology at the second round found
different results. In ARTISTIC, overall for women aged 20–64 years
non-significant differences in the cumulative detection of regres-
sive lesions were observed [157]; in Swedescreen, no difference in
the relative cumulative detection rate of CIN3 was observed, but an
increase in CIN2 (HPV versus cytology ratio, 1.56; P= 0.04) was
found among women aged 32–38 years at recruitment [158,159].
The NTCC trial reported results separately for women aged 25–
34 and 35–60 years. A significant increase in regressive lesions in
the HPV arm was found. Among women aged 35–60 years, the HPV
versus cytology ratio was 1.65 (95%CI: 1.21–2.26) for CIN3 and 1.68(95%CI: 1.25–2.26) for CIN2. A higher increase was observed in
younger women, with a HPV versus cytology ratio of 2.14 (95%CI:
1.28–3.59) for CIN3 when HPV-positive women were directly
referred for colposcopy, and of 3.11 (95%CI: 2.20–4.39) for
CIN2 with direct referral for colposcopy or with cytological triage
for HPV-positive women. [151]. These results suggest overdiagno-
sis of regressive CIN2 in younger women for HPV-based screening
compared with cytology-based screening (level of evidence: II).
What about the other harms/negative side effects/adverse effects of
cervical cancer screening?
Performance of HPV testing compared with cytology testing
When data on absolute accuracy of HPV testing from European
and North American studies were pooled, the pooled sensitivity
was 96% (95%CI: 95–98%), and the pooled specificity was 92% (95%
CI: 89–95%). The accuracy values of the hybrid capture 2 (HC2)
assay for CIN3+ were similar to those for CIN2+. Of the screened
population, 10% (95%CI: 8–12%) were high-risk HPV-positive, 1.4%
(95%CI: 1.0–1.9%) had CIN2+, and 0.8% (95%CI: 0.5–1.1%) had CIN3+.
The sensitivities of assays based on the polymerase chain reaction
(PCR) for high-grade CIN varied widely, but were consistently high
and comparable to those of HC2 in studies where the GP5+/6+
primer system was used (94–95%) [160–162].
The sensitivity of HC2, as reported in Ronco et al. [151], was on
average 34% (95%CI: 17–52%) and 21% (95%CI: 10–33%) higher than
that of cytology at the lowest cytological cut-off for the detection of
CIN2+ and CIN3+, respectively. The relative sensitivity was higher
when compared with cytology at the cut-off for the detection of
low-grade squamous intraepithelial lesions or worse (LSIL+). The
specificity of HC2 was significantly lower than that of cytology,
with a ratio of 0.97 (95%CI: 0.96–0.97) and 0.92 (95%CI: 0.89–0.95),
considering the cut-offs for atypical squamous cells of undeter-
mined significance or worse (ASC-US+) and LSIL+, respectively. PCR
was also more sensitive and less specific than cytology for
detecting CIN2+ (ratios: 1.25; 95%CI: 1.08–1.45 and 0.97; 95%CI:
0.94–1.00).
Numbers of colposcopies needed to detect 1 case of disease
To compare the potential harms of the various strategies,
Patanwala et al. [163] calculated the numbers of women who
would need to undergo colposcopy to detect one case of disease
from round 1 (CIN2+ and CIN3+, respectively) of the NTCCS, Indian,
ARTISTIC, POBASCAM, and Finnish trials. For detection of CIN2+,
significantly higher numbers of colposcopies were needed in the
HPV arm in the Indian trial [140], the NTCCS phase I trial in women
aged 35–60 years [152], and the ARTISTIC trial [157], whereas
significantly higher numbers of colposcopies were needed in the
cytology arm in the Finnish trial [164]. For detection of CIN3+,
significantly higher numbers of colposcopies were needed in the
HPV arm in the NTCCS phase I trial in women aged 35–60 years
[152] and in the ARTISTIC trial [157]. For the Indian study [140],
which reported cervical cancer rather than CIN3+ as an outcome,
the numbers of colposcopies needed to detect one case of cervical
cancer were 27.7 and 14.8 for the HPV-based and cytology-based
groups, respectively; this difference was statistically significant
(P < 0.0001). In the ARTISTIC trial, significantly higher numbers of
colposcopies were needed in the HPV co-testing arm for detection
of CIN3+ in round 1, but this did not result in increased sensitivity.
The calculated number of colposcopies needed likely under-
estimates the true number of colposcopies needed, because it
reflects the initial test positivity rate and does not include
subsequent colposcopies resulting from increased surveillance
in women who remain HPV-positive over time [163].
Potential harms related to diagnosis and treatment of CIN
Risks of colposcopy and cervical biopsy include pain, bleeding,
infection, failure to diagnose (inadequate sampling), and cost to
the patient (e.g. time off work and psychological impact). Results
from the TOMBOLA study [165], comparing cytological
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similar proportions of women with depression in the surveillance
and immediate colposcopy groups at 6 weeks after the procedure,
although women in the surveillance group were more likely to be
anxious (13.4% versus 7.9%; P < 0.001). Significantly lower pro-
portions of women in the surveillance group reported any pain
(15.0% versus 38.9%; P < 0.001), bleeding (17.2% versus 46.9%;
P < 0.001), or discharge (8.6% versus 34.2%; P < 0.001), compared
with women in the immediate colposcopy arm. An observational
study within the TOMBOLA cohort [166] reported pain, bleeding,
or discharge at 6 weeks among 14–18% of women aged 20–59 years
with colposcopy and no biopsy. Of those who had colposcopic
biopsy, 53% reported pain, 79% reported bleeding, and 46%
reported discharge. For women who had the loop electrosurgical
excision procedure (LEEP), these proportions were 67%, 87%, and
63%, respectively. The duration of bleeding and discharge was
longer for women treated by LEEP than women in the other groups
reporting these symptoms (level of evidence: II–III).
Potential harms of treatment of CIN include immediate, short-
term, and long-term risks
Cold-knife conization was significantly associated with preterm
delivery (<37 weeks: eight studies; RR, 2.59; 95%CI: 1.80–3.72), low
birth weight (<2500 g: four studies; RR, 2.53; 95%CI: 1.19–5.36), and
cesarean delivery (four studies; RR, 3.17; 95%CI: 1.07–9.40), but no
increase in perinatal mortality was seen [167]. LEEP was also
significantly associated with preterm delivery (eight studies; RR,1.7;
95%CI: 1.24–2.35), low birth weight (six studies; RR, 1.82; 95%CI:
1.09–3.06), and premature rupture of membranes (three studies; RR,
2.69; 95%CI: 1.62–4.46), but not with cesarean delivery or perinatal
mortality. Similar effects on preterm delivery were noted for laser
conization, but these were not statistically significant. No increased
risk of adverse obstetric outcomes was detected among women who
underwent laser ablation (level of evidence: III).
A 2008 review of excisional or ablative therapies found that cold-
knife conization was associated with an increased risk of preterm
birth (<30 weeks: four studies; RR, 5.33; 95%CI: 1.63–17.40;
<34 weeks: five studies; RR, 2.78; 95%CI: 1.72–4.51), low birth
weight (<2000 g: one study; RR, 2.86; 95%CI: 1.37–5.97), and
perinatal mortality (seven studies; RR, 2.87; 95%CI: 1.42–5.81) [168].
LEEP was not associated with an increased risk of perinatal mortality,
preterm birth (<32–34 weeks), or preterm labor (<28–30 weeks).
One included studyevaluated the impact of LEEP on low birth weight
and found no significant increased risk of low birth weight (<2000 or
1500 g). Ablative procedures (two studies of cryotherapy and four of
laser ablation) were not associated with an increased risk of preterm
birth, perinatal mortality, or low birth weight.
One large retrospective United States cohort study found no
increased risk of preterm birth associated with LEEP [169] (level of
evidence: III).
3.2.4. Effectiveness of prostate cancer screening
Is PSA testing for prostate cancer screening effective in reducing
prostate cancer mortality and overall mortality for the male
population at average risk by age range?
To date, five RCTs (the Quebec study, the Stockholm study, the
Norrkoping study, the European Randomized Study of Screening
for Prostate Cancer [ERSPC], and the United States Prostate, Lung,
Colorectal and Ovarian [PLCO] Cancer Screening Trial) comparing
mass screening for prostate cancer to no screening have assessed
the efficacy of screening men for prostate cancer in reducing
prostate cancer-specific and all-cause mortality.
The Quebec study recruited men aged 45–80 years in Canada,
providing annual screening with combination digital rectal
examination (DRE) and prostate-specific antigen (PSA) testing.
Participants were followed up over an 11-year period. The cut-off
for biopsy was PSA >3.0 ng/mL [170]. The Stockholm studyrecruited men aged 55–70 years in Sweden for a one-time
screening using DRE, PSA, and transrectal ultrasound (TRUS).
Participants were followed up over a 15-year period. The cut-off for
biopsy was PSA >10.0 ng/mL, with repeat TRUS performed for PSA
>7.0 ng/mL [171]. The Norrkoping study recruited men aged 50–
69 years in Sweden and screened every 3 years. During the initial
phase of the study, only DRE was offered; however, the screening
regimen later evolved to include both DRE and PSA testing.
Participants were followed up over a 20-year period. The cut-off for
biopsy was PSA >4.0 ng/mL [172]. The PLCO study recruited men
aged 55–74 years in the United States for annual screening with
DRE and PSA. Participants were followed up over a 10–13-year
period. Patients were advised for diagnostic evaluation when PSA
exceeded 4.0 ng/mL [173]. The ERSPC recruited men aged 50–
74 years across nine European countries. Screening regimens
varied across participating sites, with cut-off values for biopsy
ranging from PSA >2.5, to 3.0, 4.0, and 10.0 ng/mL. The screening
interval in six of the sites was 4 years [174].
The methodological quality of the RCTs was assessed for the risk
of bias by Ilic et al. [175]. The Quebec, Stockholm, and Norrkoping
trials were assessed as having a high risk of bias. The ERSPC and the
PLCO Cancer Screening Trial were assessed as having a low risk of
bias, but provided contradictory results. The ERSPC reported a
significant reduction in prostate-cancer-specific mortality (RR,
0.84; 95%CI: 0.73–0.95) [174]; the PLCO study concluded that there
was no significant benefit (RR, 1.15; 95%CI: 0.86–1.54) [173].
However, high risk of contamination (45% of the control group
had PSA opportunistic screening in the 3 years preceding
randomization, and 52% during the time period of the last round
of screening in the intervention arm) and high level of loss to
follow-up (43%) in the PLCO study suggest the likelihood of
contamination and selection bias. In conclusion, one RCT of good
quality showed an overall significant reduction in prostate cancer-
specific mortality, that was higher when considering the core age
group (55–69 years) of the study and those aged 65–69 years;
however results from the other available RCTs at high risk of bias
are in the opposite direction (level of evidence: II).
4. Conclusions
According to the evidence retrieved on the incidence and
mortality of screening according to age and intervals between
tests, and on side effects of colorectal, breast, and cervical cancer
screening, the 4th edition of the European Code against Cancer
recommends that men and women take part in organized cancer
screening programs for colorectal cancer and that women take part
in organized cancer screening programs for breast and cervical
cancer.
Organized screening programs are recommended, in order to
achieve the greatest benefit with the least harm. Screening is
recommended only for those cancers where a demonstrated life-
saving effect substantially outweighs the potential harm of
examining very large numbers of people who may otherwise
never have, or suffer from, these cancers. Screening programs are
expected to provide routine factual evidence of the balance
between benefits and harms. The WG agreed that the of evidence
on benefits and harms for screening of other cancers, such as
prostate or lung cancers, at the time of the preparation of the Code
was not sufficiently available to recommend EU citizens to
participate in screening outside research programs, designed for
evaluation and implementation purposes.
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